Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This is a randomized Phase II trial to study the effectiveness and toxicity of neoadjuvant
and adjuvant PD-1 antibody Toripalimab combined with concurrent cisplatin chemoradiotherapy
versus cisplatin concurrent chemoradiotherapy plus placebo in treating patients with high
risk locoregionally advanced nasopharyngeal carcinoma.